Legal & General Group Plc increased its stake in shares of Alkermes PLC (NASDAQ:ALKS) by 10.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 654,744 shares of the company’s stock after buying an additional 60,624 shares during the period. Legal & General Group Plc owned 0.43% of Alkermes PLC worth $37,956,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALKS. Daiwa SB Investments Ltd. bought a new position in shares of Alkermes PLC during the second quarter valued at $166,000. Greenwood Capital Associates LLC increased its position in shares of Alkermes PLC by 2.4% in the first quarter. Greenwood Capital Associates LLC now owns 3,729 shares of the company’s stock valued at $218,000 after buying an additional 89 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its position in shares of Alkermes PLC by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock valued at $222,000 after buying an additional 224 shares during the last quarter. US Bancorp DE increased its position in shares of Alkermes PLC by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after buying an additional 3,122 shares during the last quarter. Finally, Insight Capital Research & Management Inc. bought a new position in shares of Alkermes PLC during the second quarter valued at $232,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Shares of Alkermes PLC (NASDAQ ALKS) opened at 49.16 on Wednesday. The company has a 50-day moving average price of $54.65 and a 200 day moving average price of $56.99. Alkermes PLC has a 12-month low of $41.93 and a 12-month high of $63.40. The company’s market capitalization is $7.55 billion.

Alkermes PLC (NASDAQ:ALKS) last posted its earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. The business had revenue of $218.80 million during the quarter, compared to the consensus estimate of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The business’s quarterly revenue was up 12.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.01) EPS. On average, equities analysts anticipate that Alkermes PLC will post ($0.04) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Legal & General Group Plc Has $37.96 Million Position in Alkermes PLC (ALKS)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/30/legal-general-group-plc-has-37-96-million-position-in-alkermes-plc-alks.html.

ALKS has been the subject of several analyst reports. Credit Suisse Group set a $70.00 price target on Alkermes PLC and gave the company a “buy” rating in a report on Friday, May 19th. J P Morgan Chase & Co set a $78.00 price target on Alkermes PLC and gave the company a “buy” rating in a report on Saturday, July 1st. Jefferies Group LLC set a $69.00 price target on Alkermes PLC and gave the company a “buy” rating in a report on Friday, August 25th. Zacks Investment Research upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $62.89.

In other Alkermes PLC news, insider Shane Cooke sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $60.33, for a total transaction of $603,300.00. Following the completion of the sale, the insider now directly owns 84,708 shares of the company’s stock, valued at approximately $5,110,433.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $54.91, for a total value of $82,365.00. Following the sale, the director now directly owns 9,500 shares of the company’s stock, valued at $521,645. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,500 shares of company stock valued at $859,065. 5.34% of the stock is owned by company insiders.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.